JP2004175680A - Mineral-containing composition having improving effect on biological balance - Google Patents
Mineral-containing composition having improving effect on biological balance Download PDFInfo
- Publication number
- JP2004175680A JP2004175680A JP2002340508A JP2002340508A JP2004175680A JP 2004175680 A JP2004175680 A JP 2004175680A JP 2002340508 A JP2002340508 A JP 2002340508A JP 2002340508 A JP2002340508 A JP 2002340508A JP 2004175680 A JP2004175680 A JP 2004175680A
- Authority
- JP
- Japan
- Prior art keywords
- suppression
- mineral
- containing composition
- aware
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 26
- 239000011707 mineral Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title claims abstract description 15
- 230000001629 suppression Effects 0.000 claims abstract description 70
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 230000036772 blood pressure Effects 0.000 claims abstract description 18
- 206010030113 Oedema Diseases 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 206010019233 Headaches Diseases 0.000 claims abstract description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000037182 bone density Effects 0.000 claims abstract description 11
- 239000011575 calcium Substances 0.000 claims abstract description 11
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 11
- 231100000869 headache Toxicity 0.000 claims abstract description 11
- 239000011777 magnesium Substances 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- 235000014653 Carica parviflora Nutrition 0.000 claims abstract description 10
- 206010033557 Palpitations Diseases 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 10
- 235000019738 Limestone Nutrition 0.000 claims abstract description 5
- 239000006028 limestone Substances 0.000 claims abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 11
- 230000036506 anxiety Effects 0.000 claims description 11
- 208000032140 Sleepiness Diseases 0.000 claims description 10
- 206010041349 Somnolence Diseases 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 244000132059 Carica parviflora Species 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 9
- 206010000059 abdominal discomfort Diseases 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 9
- 230000006793 arrhythmia Effects 0.000 claims description 9
- 201000006549 dyspepsia Diseases 0.000 claims description 9
- 208000024798 heartburn Diseases 0.000 claims description 9
- 229940116269 uric acid Drugs 0.000 claims description 9
- 241000218996 Passiflora Species 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 239000011574 phosphorus Substances 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 208000010444 Acidosis Diseases 0.000 claims description 7
- 230000007950 acidosis Effects 0.000 claims description 7
- 208000026545 acidosis disease Diseases 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 7
- 240000003538 Chamaemelum nobile Species 0.000 claims description 6
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 6
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 6
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 240000001432 Calendula officinalis Species 0.000 claims description 5
- 244000020551 Helianthus annuus Species 0.000 claims description 5
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 5
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 5
- 230000004397 blinking Effects 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000001102 lavandula vera Substances 0.000 claims description 5
- 235000018219 lavender Nutrition 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- 235000011201 Ginkgo Nutrition 0.000 claims description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 4
- 244000194101 Ginkgo biloba Species 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- 244000144927 Aloe barbadensis Species 0.000 claims description 3
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 244000025221 Humulus lupulus Species 0.000 claims description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 3
- 244000141009 Hypericum perforatum Species 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 3
- 244000062730 Melissa officinalis Species 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 235000011925 Passiflora alata Nutrition 0.000 claims description 3
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 3
- 235000011922 Passiflora incarnata Nutrition 0.000 claims description 3
- 235000013750 Passiflora mixta Nutrition 0.000 claims description 3
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims description 3
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 3
- 240000003444 Paullinia cupana Species 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 241000269851 Sarda sarda Species 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 3
- 244000126014 Valeriana officinalis Species 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- 229950001002 cianidanol Drugs 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 150000001982 diacylglycerols Chemical class 0.000 claims description 3
- 102000018146 globin Human genes 0.000 claims description 3
- 108060003196 globin Proteins 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000003531 protein hydrolysate Substances 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- 229940026510 theanine Drugs 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000016788 valerian Nutrition 0.000 claims description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 2
- 241000906543 Actaea racemosa Species 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 2
- 244000020518 Carthamus tinctorius Species 0.000 claims description 2
- 241000195955 Equisetum hyemale Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 235000002823 Mahonia aquifolium Nutrition 0.000 claims description 2
- 244000179291 Mahonia aquifolium Species 0.000 claims description 2
- 241000899950 Salix glauca Species 0.000 claims description 2
- 235000006468 Thea sinensis Nutrition 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 235000020333 oolong tea Nutrition 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 244000165082 Lavanda vera Species 0.000 claims 2
- 240000002234 Allium sativum Species 0.000 claims 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 claims 1
- 240000003829 Sorghum propinquum Species 0.000 claims 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims 1
- 241000219793 Trifolium Species 0.000 claims 1
- 235000004611 garlic Nutrition 0.000 claims 1
- 229940087559 grape seed Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 208000019622 heart disease Diseases 0.000 abstract description 4
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 239000003925 fat Substances 0.000 abstract 2
- 241000243321 Cnidaria Species 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 32
- 238000011156 evaluation Methods 0.000 description 23
- 230000037406 food intake Effects 0.000 description 23
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 244000178870 Lavandula angustifolia Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 241000754798 Calophyllum brasiliense Species 0.000 description 2
- 241000132536 Cirsium Species 0.000 description 2
- 206010016029 Face oedema Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000014987 limb edema Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- NPQAMUFQEFLLCY-UHFFFAOYSA-N Sageone Chemical compound C1=2C(O)=C(O)C(C(C)C)=CC=2CCC2=C1C(=O)CCC2(C)C NPQAMUFQEFLLCY-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- MCOQHIWZJUDQIC-UHFFFAOYSA-N barban Chemical compound ClCC#CCOC(=O)NC1=CC=CC(Cl)=C1 MCOQHIWZJUDQIC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000021549 curry roux Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- RCVGXYUBWJMZTF-MGPUTAFESA-N sageone Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C=O)C1=C2C=C(C(C)C)C(O)=C1O RCVGXYUBWJMZTF-MGPUTAFESA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制の作用を有することを特徴とする生体バランス改善効果を備えたミネラル含有組成物に関するものである。更に詳しくは、天然から産出されるサンゴ化石又は、海洋生物由来鉱物の利用技術に関するものである。
【0002】
【従来の技術】
日本には現在1000万人の骨粗しょう症患者、1200万人の高血圧患者、500万人の高脂血漿症患者、50万人の腎臓病患者、800万人の胃腸病患者、多数の高中性脂肪病及び心臓病患者、多数の高尿酸患者、多数の更年期症状患者がいると言われている。骨粗しょう症、高血圧症、高脂血漿症、高中性脂肪症、心臓病、高尿酸血症などは遺伝性の他、偏った食生活と運動不足などに起因する生活習慣病とも言われている。従って、それら疾患は日常の食生活を十分配慮する事により予防可能な疾患である。
【0003】
また、筋肉のれん縮が原因と言われている瞼の瞬きや頭痛、手足・顔の浮腫はマグネシウム不足によると考えられている。不安や怒り、いらいら、興奮などの原因である脳のα波低下などはカルシウムとマグネシウム不足によると考えられている。腎臓病に付随する血圧上昇、高カリウム血漿、アシドーシス、高リン血漿、浮腫、貧血などはカルシウムとマグネシウムの摂取不足と考えられている。さらに、胸焼けや胃部不快感、高尿酸値よる各種結石の生成と痛風は、アルカリ性食品の摂取不足と考えられている。
【0004】
【発明が解決しようとする課題】
従って、このようなミネラルを日常生活の中で気軽に摂取できる天然の産物があれば、骨粗しょう症、高血圧症、高脂血漿症、高中性脂肪症、心臓病、高尿酸血症、胃腸病、更年期症やそれらの疾患の予備軍を減らすことが出来る。
【0005】
ここに本出願発明者は各種天然の産物でこのような効果を有するものを検討した結果、本願発明に到達したものであり、本願発明の課題は、日常生活の中で気軽に摂取できる天然産物であって、骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制などの生体バランス改善効果を備えたミネラル含有組成物を提供することにある。
【0006】
【課題を解決するための手段】
上記課題を解決するために、本発明を適用したミネラル含有組成物は、天然から産出されたサンゴ化石、又は海洋生物から生成した石灰岩中のカルシウムが海中のマグネシウムで置換されて鉱物化してなる海洋生物由来の鉱物を含有し、骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制などの生体バランス改善効果を備えていることを特徴とする。
【0007】
本発明において、前記サンゴ化石または前記海洋生成物由来の鉱物には、カルシウムとマグネシウムが2対1から19対1の割合で含まれていることが好ましい。
【0008】
本発明において、更に、杜仲葉配糖体、ラクトトリペプチド、サーデンペプチド、かつお節オリゴペプチド、難消化デキストリン、グロビン蛋白分解物、ジアシルグリセロール、キトサン、大豆蛋白質、低分子アルギン酸ナトリウム、テアニン、カテキン、フィトステロールのうち少なくとも1つの成分が配合されていることが好ましい。
【0009】
本発明において、更に、ザクロ、ガラナ、セイヨウオトギリソウ、エゾウコギ、セイヨウカノコソウ、トケイソウ、カミツレ、ホップ、レモンバーム、ローズマリー、アロエベラ、コウジン、ニガウリ、ラベンダー、マリーゴールド、カモミール、パッションフラワー、マリアザミ、ヒマワリ、キャックロウ、イチョウ、ブドウ種子、ブラックコホシュ、紅花、オレゴングレープ、ラベンダー、ヒマワリ、エキナキア、キャックロウ、カレンジュラ、スギナ、ツボクサ、リュウガンニク、メドスイート、アンジェリカ、トケイソウ、お茶、ウーロン茶、バーベイン、ホワイトウイロー、カギカズラのエキスのうち少なくとも1つの成分が配合されていることが好ましい。
【0010】
本発明において、更に、銅酵母、セレン酵母、マンガン酵母のうち少なくとも1つの成分が配合されていることが好ましい。
【0011】
【発明の実施の形態】
本発明に係るミネラル含有組成物は、天然から産出されたサンゴ化石、又は海洋生物から生成した石灰岩中のカルシウムが海中のマグネシウムで置換されて鉱物化してなる海洋生物由来の鉱物を含有しており、以下、各種臨床結果などを示すように、骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制などの生体バランス改善効果を備えている。
【0012】
ここで、サンゴ化石または海洋生成物由来の鉱物としては、カルシウムとマグネシウムが2対1から19対1の割合で含まれているものを用いることが好ましい。
【0013】
また、本発明では、生体バランス改善効果をさらに高めることを目的に、杜仲葉配糖体、ラクトトリペプチド、サーデンペプチド、かつお節オリゴペプチド、難消化デキストリン、グロビン蛋白分解物、ジアシルグリセロール、キトサン、大豆蛋白質、低分子アルギン酸ナトリウム、テアニン、カテキン、フィトステロールのうち少なくとも1つの成分を配合することがある。また、ザクロ、ガラナ、セイヨウオトギリソウ、エゾウコギ、セイヨウカノコソウ、トケイソウ、カミツレ、ホップ、レモンバーム、ローズマリー、アロエベラ、コウジン、ニガウリ、ラベンダー、マリーゴールド、カモミール、パッションフラワー、マリアザミ、ヒマワリ、キャックロウ、イチョウ、ブドウ種子、ブラックコホシュ、紅花、オレゴングレープ、ラベンダー、ヒマワリ、エキナキア、キャックロウ、カレンジュラ、スギナ、ツボクサ、リュウガンニク、メドスイート、アンジェリカ、トケイソウ、お茶、ウーロン茶、バーベイン、ホワイトウイロー、カギカズラのエキスのうち少なくとも1つの成分を配合してもよい。更に、銅酵母、セレン酵母、マンガン酵母のうち少なくとも1つの成分を配合してもよい。
【0014】
このような構成のミネラル含有組成物に関して、臨床試験などを行った結果を以下に説明する。
【0015】
[評価1]
平均年齢45歳の男女22例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前の平均血圧は140.2mmHgであったが、3カ月後の平均値は132.5mmHgへ低下した。この集団の平均年齢の正常血圧は139mmHg以下であるので、血圧は正常化したといえる。
【0016】
[評価2]
平均年齢45歳の男女22例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前の平均骨密度は0.27025であったが、3カ月後の平均値は0.28856へ上昇した。この集団の平均年齢の正常骨密度は0.27986以上でなので平均骨密度は正常化した。なお、骨密度の測定はアロカ株式会社製AOS−100超音波装置を使用した。
【0017】
[評価3]
平均年齢45歳の男女22例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前の平均中性脂肪値は190.3mg/dlであったが、3カ月後の平均値は130.8mg/dlへ低下した。この集団の平均年齢の正常中性脂肪値は55−150mg/dlであるので、平均中性脂肪値は正常化したといえる。
【0018】
[評価4]
平均年齢45歳の男女22例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前の平均コレステロール値は229.5mg/dlであったが、3カ月後の平均値は218.8mg/dlへ低下した。この集団の平均年齢の正常コレステロール値は120−220mg/dlであるので、平均コレステロール値は正常化したといえる。
【0019】
[評価5]
平均年齢45歳の男女22例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前の平均HDL値は51.7mg/dlであったが、3カ月後の平均値は56.1mg/dlへ上昇した。この集団の平均年齢の正常コレステロール値は50−70mg/dlであるので、平均HDL値はより一層、正常化したといえる。
【0020】
[評価6]
「動悸」を自覚した平均年齢50歳の男女9例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く、8例が弱く自覚した。3カ月後7例が動悸を全く自覚せず、2例が弱く自覚したが、全体として動悸が改善されたといえる。
【0021】
[評価7]
「瞼の瞬き」を自覚した平均年齢52歳の男女6例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前8例が弱く自覚した。3カ月後5例が瞬きを全く自覚せず、1例が弱く自覚したが、全体として瞬きが改善されたといえる。
【0022】
[評価8]
「頭痛」を自覚した平均年齢45歳の男女6例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、5例が弱く自覚した。3カ月後5例が頭痛を全く自覚せず、1例が弱く自覚したが、全体として頭痛が改善されたといえる。
【0023】
[評価9]
手足顔の浮腫を自覚した平均年齢43歳の男女10例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、9例が弱く自覚した。3カ月後5例が浮腫を全く自覚せず、4例が弱く1例が強く自覚したが、全体として手足顔の浮腫が改善されたといえる。
【0024】
[評価10]
「怒り易い」を自覚した平均年齢47歳の男女15例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、14例が弱く自覚した。3カ月後12例が「怒り易い」を全く自覚せず、2例が弱く1例が強く自覚したが、全体として「怒り易い」が改善されたといえる。
【0025】
[評価11]
「不安」を自覚した平均年齢45歳の男女11例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、10例が弱く自覚した。3カ月後7例が「不安」を全く自覚せず、3例が弱く1例が強く自覚したが、全体として「不安」が改善されたといえる。
【0026】
[評価12]
「いらいら」を自覚した平均年齢40歳の男女16例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、10例が普通程度の自覚をし、14例が弱く自覚した。3カ月後7例が「いらいら」を全く自覚せず、9例が弱く自覚したが、全体として「いらいら」が改善されたといえる。
【0027】
[評価13]
「興奮」を自覚した平均年齢42歳の男女11例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が強く自覚し、10例が弱く自覚した。3カ月後6例が「興奮」を全く自覚せず、4例が弱く自覚したが、全体として「興奮」が改善されたといえる。
【0028】
[評価14]
「肩こり」を自覚した平均年齢45歳の男女17例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前5例が強く自覚し、7例が普通程度の自覚をし、3例が弱く自覚した。3カ月後6例が「肩こり」を全く自覚せず、6例が弱く自覚したが、全体として「肩こり」が改善されたといえる。
【0029】
[評価15]
「だるさ」を自覚した平均年齢43歳の男女14例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前7例が普通程度の自覚をし、11例が弱く自覚した。3カ月後5例が「だるさ」を全く自覚せず、8例が弱く自覚したが、全体として「だるさ」が改善されたといえる。
【0030】
[評価16]
「ぼんやり感」を自覚した平均年齢47歳の男女8例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前1例が普通程度の自覚をし、7例が弱く自覚した。3カ月後4例が「ぼんやり感」を全く自覚せず、3例が弱く自覚したが、全体として「ぼんやり感」が改善されたといえる。
【0031】
[評価17]
「傾眠」を自覚した平均年齢43歳の男女13例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前3例が強く自覚し、10例が普通程度の自覚をした。3カ月後5例が「傾眠」を全く自覚せず、3例が弱く自覚したが、全体として「傾眠」が改善されたといえる。
【0032】
[評価18]
「不整脈」を自覚した平均年齢48歳の男女6例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前6例が強く自覚した。3カ月後4例が「不整脈」を全く自覚せず、2例が弱く自覚したが、全体として「不整脈」が改善されたといえる。
【0033】
[評価19]
平均年齢20歳の男女12例が、数字穴埋めゲームなどによるストレスを与えられた後、サンゴカルシウム1500mgを摂取した。一方、同様なストレスを与えられた同様な対照集団は、デキリストリン1500mgを摂取した。脳波は日本電気株式会社EE1000型14チャネル多用脳波計で測定され、脳波を頭部14箇所から導出し、主としてα波の帯域(8−12Hz)の脳波に付き、α波含有量やα波トポグラフィーにより解析した。α波はリラックス状態時出現する脳波であり、増加するとリラックスし「怒り易い」や「不安」が改善されると言われている。
【0034】
サンゴカルシウム1500mgを摂取した集団のα波は、摂取5分後0.0μV、30分後1.0μVに増加した。一方、デキリストリン1500mgを摂取した対照集団のα波は、摂取5分後1.8μV、30分後0.5μVに減少した。
【0035】
このα波をリラックスに重要な右脳だけでみると、サンゴカルシウム1500mg摂取した集団は、5分後が50μVで、10分後は59μVと上昇した。
【0036】
一方、デキリストリン1500mgを摂取した対照集団では、5分後が40μVで、10分後は30μVへ低下した。
【0037】
次に、頭頂のα波についてみると、サンゴカルシウム1500mg摂取した集団は、5分後が2.1μVで、10分後は3.1μV、20分後は3.4と上昇した。一方、デキリストリン1500mgを摂取した対照集団は、5分後が3.0μVで、10分後は2.5μV、20分後は2.0μVへ低下した。
【0038】
[評価20]
20代の男性2名がサンゴカルシウム200mgを含む飴を摂取した。ケミカル機器株式会社製の2チャネルメモリPH測定器を使用し、胃内と噴門部にPHセンサーを設置し、胃内のPHおよび食道下部のPHを測定した。飴摂取前の胃内のPHは1−2で、食道下部PHは6を示した。
【0039】
また、飴を1粒食べると胃内のPHは、3または4に上昇し、食道下部PHは7に上昇した。また、飴2粒、3粒、4粒を食べた時も同様の事が観察された。
【0040】
以上の様にサンゴカルシウム200mgを含む飴により、胃及び食道下部のPHが中和される事が判明したので、臨床試験を実施した。
【0041】
胸焼けの症状を示す平均年齢50代9名がサンゴカルシウム200mgを含む飴を1−2個を摂取した。9例全例に、胸焼け症状の消出が認められた。胃部不快感症状を示す平均年齢50代10名がサンゴカルシウム200mgを含む飴を1−2個を摂取した。2例に胃部不快感症状の消出が認められ、8例に改善が認められた。
【0042】
[評価21]
高尿酸血症の男4名が、サンゴカルシウム900mg含有錠剤を1日3回、またはカルシウム40mgとマグネシウム20mgとを含むPH8−9のサンゴカルシウム水500mlを毎日、6カ月間摂取した。摂取前の血清尿酸値平均は9.0mg/dlであったが、3カ月後、平均値は6.0mg/dl迄低下し、痛風の痛みも軽減し、四肢の結石または尿路結石も改善された。
【0043】
[評価22]
血清クレアチニン値が高い腎臓病の男4例が、サンゴカルシウム900mg含有錠剤を1日3回、3カ月間摂取した。摂取前平均血清クレアチニン値は6.7mg/dlであったが、6カ月後5.5mg/dl迄低下した。また、これらの患者の摂取前平均血圧は、160.21mmHgあったが、6カ月後の平均値は140.54mmHgへ低下した。摂取前平均血清カリウムは5.0mEq/lであったが、3カ月後の平均値は4.0mEq/l迄低下した。
【0044】
[評価23]
腎臓病の男3例が、サンゴカルシウム900mg含有錠剤を1日3回、6カ月間摂取した。摂取前平均リン値は5.0mg/dlであったが、3カ月後は4.2mg/dl迄低下し、浮腫も改善された。
【0045】
又、摂取前平均血清鉄値は40μg/dlであったが、3カ月後は60μg/dl迄増加した。
【0046】
[サンゴカルシウムの摂取形態]
上記の効果を示すサンゴカルシウムの摂取形態としては、単独もしくは他成分との配合における、錠剤、カプセル剤、散剤、顆粒剤、ふりかけ剤の他、飴、ガム、チョコレート、クッキー・スナック、ゼリーなどの菓子類、各種レトルト食品、カレーのルー、シチュウ、麺類、牛乳など各種食品への配合、飲料などである。
【0047】
【発明の効果】
以上説明したように、本発明に係るミネラル含有組成物は、天然から産出されたサンゴ化石、又は海洋生物から生成した石灰岩中のカルシウムが海中のマグネシウムで置換されて鉱物化してなる海洋生物由来の鉱物を含有しており、日常生活の中で気軽に摂取できる。また、骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制などの生体バランス改善効果を備えている。[0001]
BACKGROUND OF THE INVENTION
The present invention increases bone density, lowers blood pressure, lowers total cholesterol, lowers triglycerides, increases HDL, suppresses arrhythmias, suppresses palpitation, suppresses blinking, suppresses headache, improves edema of limbs / face, suppresses anxiety and anger, irritability Suppression, suppression of excitement, suppression of stiff shoulders, suppression of dullness, suppression of dullness, suppression of somnolence, increase of alpha wave in the brain, improvement of heartburn and stomach discomfort due to neutralization of gastric acid, reduction of high uric acid level, kidney A mineral-containing composition having a biological balance improving effect characterized by suppressing blood pressure elevation associated with disease, inhibiting high potassium plasma, inhibiting acidosis, inhibiting high phosphorus plasma, inhibiting edema, and inhibiting anemia It is about. More specifically, the present invention relates to a technology for utilizing coral fossils produced from nature or marine organism-derived minerals.
[0002]
[Prior art]
There are currently 10 million osteoporosis patients, 12 million hypertensive patients, 5 million hyperlipidemic plasma patients, 500,000 kidney disease patients, 8 million gastrointestinal disease patients, and many high neutrality patients in Japan. It is said that there are patients with steatosis and heart disease, a number of patients with high uric acid, and a number of patients with climacteric symptoms. Osteoporosis, hypertension, hyperlipidemia, hypertriglyceridosis, heart disease, hyperuricemia, etc. are also said to be lifestyle-related diseases due to hereditary diet and lack of exercise. . Therefore, these diseases are diseases that can be prevented by giving careful consideration to daily eating habits.
[0003]
In addition, blinking of the eyelids, headache, and edema of the limbs and face, which are said to be caused by muscle spasm, are thought to be due to magnesium deficiency. It is thought that a decrease in the alpha wave of the brain, which causes anxiety, anger, annoyance, and excitement, is due to a lack of calcium and magnesium. Increased blood pressure, high potassium plasma, acidosis, high phosphorus plasma, edema, anemia, etc. associated with kidney disease are considered to be insufficient intake of calcium and magnesium. Furthermore, heartburn, stomach discomfort, the formation of various stones due to high uric acid levels, and gout are considered insufficient intake of alkaline foods.
[0004]
[Problems to be solved by the invention]
Therefore, if there are natural products that can be easily consumed in daily life, osteoporosis, hypertension, hyperlipidemia, hypertriglyceridosis, heart disease, hyperuricemia, gastrointestinal disease , Reduce menopause and reserves of those diseases.
[0005]
As a result of studying various natural products having such an effect, the present inventor has arrived at the present invention, and the subject of the present invention is a natural product that can be easily consumed in daily life. Bone density enhancement, blood pressure reduction, total cholesterol reduction, triglyceride reduction, HDL increase, arrhythmia suppression, palpitation suppression, blink suppression, headache suppression, limb / face edema improvement, anxiety and anger suppression, irritability Suppression, suppression of excitement, suppression of stiff shoulders, suppression of dullness, suppression of dullness, suppression of somnolence, increase of alpha wave in the brain, improvement of heartburn and stomach discomfort due to neutralization of gastric acid, reduction of high uric acid level, kidney An object of the present invention is to provide a mineral-containing composition having a biological balance improving effect such as suppression of blood pressure increase associated with disease, suppression of high potassium plasma, suppression of acidosis, suppression of high phosphorus plasma, suppression of edema, and suppression of anemia.
[0006]
[Means for Solving the Problems]
In order to solve the above-mentioned problems, a mineral-containing composition to which the present invention is applied is a coral fossil produced from nature, or a marine product in which calcium in limestone produced from marine organisms is mineralized by substituting magnesium in the ocean. Contains biological minerals, strengthens bone density, lowers blood pressure, lowers total cholesterol, lowers neutral fat, increases HDL, suppresses arrhythmia, suppresses palpitation, suppresses blinking, suppresses headache, improves edema of limbs and face, anxiety and anger Suppression, annoyance, suppression of excitement, suppression of stiff shoulders, suppression of dullness, suppression of dullness, suppression of somnolence, increase of alpha waves in the brain, improvement of heartburn and stomach discomfort by neutralization of gastric acid, high uric acid level It has biological balance improvement effects such as reduction of blood pressure, suppression of blood pressure increase associated with kidney disease, suppression of high potassium plasma, suppression of acidosis, suppression of high phosphorus plasma, suppression of edema, suppression of anemia, etc. It is characterized in.
[0007]
In the present invention, the coral fossil or the mineral derived from the marine product preferably contains calcium and magnesium in a ratio of 2: 1 to 19: 1.
[0008]
In the present invention, further, nakanaka leaf glycoside, lactotripeptide, sadden peptide, bonito oligopeptide, indigestible dextrin, globin proteolysate, diacylglycerol, chitosan, soy protein, low molecular weight sodium alginate, theanine, catechin, It is preferable that at least one component of phytosterol is blended.
[0009]
In the present invention, pomegranate, guarana, Hypericum perforatum, Ezoukogi, valerian serrata, passiflora, chamomile, hops, lemon balm, rosemary, aloe vera, kojin, bitter gourd, lavender, marigold, chamomile, passion flower, maria thistle, sunflower, cough Extract Of these, at least one component is preferably blended.
[0010]
In the present invention, it is preferable that at least one component of copper yeast, selenium yeast, and manganese yeast is further blended.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
The mineral-containing composition according to the present invention contains a coral fossil produced from nature, or a mineral derived from marine organisms, in which calcium in limestone produced from marine organisms is mineralized by substituting magnesium in the ocean. In the following, as shown by various clinical results, bone density enhancement, blood pressure reduction, total cholesterol reduction, triglyceride reduction, HDL increase, arrhythmia suppression, palpitation suppression, blink suppression, headache suppression, limb / face edema improvement , Suppression of anxiety and anger, suppression of annoyance, suppression of excitement, suppression of stiff shoulders, suppression of dullness, suppression of dullness, suppression of somnolence, increase of brain alpha waves, improvement of heartburn and stomach discomfort by neutralizing gastric acid , Improvement of biological balance such as reduction of high uric acid level, suppression of blood pressure increase associated with kidney disease, suppression of high potassium plasma, suppression of acidosis, suppression of high phosphorus plasma, suppression of edema, suppression of anemia It is equipped with a.
[0012]
Here, as the coral fossil or marine product-derived mineral, it is preferable to use a mineral containing calcium and magnesium in a ratio of 2: 1 to 19: 1.
[0013]
Moreover, in the present invention, for the purpose of further enhancing the effect of improving the balance of living body, nakanaka leaf glycoside, lactotripeptide, sadden peptide, bonito oligopeptide, indigestible dextrin, globin proteolysate, diacylglycerol, chitosan, At least one component of soy protein, low molecular weight sodium alginate, theanine, catechin, and phytosterol may be blended. Also, pomegranate, guarana, Hypericum perforatum, Ezocogi, valerian fragrance, passiflora, chamomile, hops, lemon balm, rosemary, aloe vera, kojin, bitter gourd, lavender, marigold, chamomile, passion flower, maria thistle, sunflower, ginkgo, ginkgo, ginkgo At least one of seeds, black cohosh, safflower, oregon grape, lavender, sunflower, echinakia, cucklow, calendula, horsetail, boxweed, longannik, med sweet, angelica, passiflora, tea, oolong tea, barbane, white willow, sage One component may be blended. Furthermore, you may mix | blend at least 1 component among copper yeast, selenium yeast, and manganese yeast.
[0014]
The results of clinical tests and the like regarding the mineral-containing composition having such a configuration will be described below.
[0015]
[Evaluation 1]
Twenty-two men and women with an average age of 45 years took tablets containing 900 mg of coral calcium three times a day for three months. The average blood pressure before ingestion was 140.2 mmHg, but the average value after 3 months dropped to 132.5 mmHg. Since the normal blood pressure of the average age of this group is 139 mmHg or less, it can be said that the blood pressure has been normalized.
[0016]
[Evaluation 2]
Twenty-two men and women with an average age of 45 years took tablets containing 900 mg of coral calcium three times a day for three months. The average bone density before ingestion was 0.27025, but the average value after 3 months rose to 0.28856. Since the average bone density of this group was 0.27986 or more, the average bone density was normalized. The bone density was measured using an AOS-100 ultrasonic device manufactured by Aloka Corporation.
[0017]
[Evaluation 3]
Twenty-two men and women with an average age of 45 years took tablets containing 900 mg of coral calcium three times a day for three months. The average triglyceride value before ingestion was 190.3 mg / dl, but the average value after 3 months decreased to 130.8 mg / dl. Since the average triglyceride value of the average age of this population is 55-150 mg / dl, it can be said that the average triglyceride value was normalized.
[0018]
[Evaluation 4]
Twenty-two men and women with an average age of 45 years took tablets containing 900 mg of coral calcium three times a day for three months. The average cholesterol level before ingestion was 229.5 mg / dl, but the average value after 3 months was reduced to 218.8 mg / dl. Since the normal cholesterol value of the average age of this group is 120-220 mg / dl, it can be said that the average cholesterol value was normalized.
[0019]
[Evaluation 5]
Twenty-two men and women with an average age of 45 years took tablets containing 900 mg of coral calcium three times a day for three months. The average HDL value before intake was 51.7 mg / dl, but the average value after 3 months increased to 56.1 mg / dl. Since the normal cholesterol value of the average age of this population is 50-70 mg / dl, it can be said that the average HDL value was further normalized.
[0020]
[Evaluation 6]
Nine men and women with an average age of 50 who were aware of “palpitations” took tablets containing 900 mg of coral calcium three times a day for three months. One patient was aware that one was strong and 8 were weak before ingestion. Three months later, 7 cases were not aware of palpitation at all and 2 cases were weakly aware, but it can be said that palpitation improved as a whole.
[0021]
[Evaluation 7]
Six men and women with an average age of 52 who were aware of “blinks of moths” ingested tablets containing 900 mg of coral calcium three times a day for three months. Eight cases were noticed weakly before ingestion. After 3 months, 5 cases were not aware of the blink at all, and one was weakly aware, but it can be said that the blink was improved as a whole.
[0022]
[Evaluation 8]
Six men and women with an average age of 45 years who were aware of “headache” took tablets containing 900 mg of coral calcium three times a day for three months. One patient was strongly aware before ingestion and five were weakly aware. After 3 months, 5 cases did not notice any headaches, and one case was weakly aware, but it can be said that the headaches as a whole improved.
[0023]
[Evaluation 9]
Ten men and women with an average age of 43 years who were aware of edema on the limbs and face took tablets containing 900 mg of coral calcium three times a day for three months. One patient was strongly aware before ingestion and nine were weakly aware. Three months later, 5 cases were not aware of edema at all, 4 cases were weak and 1 case was strongly aware, but it can be said that edema of the limbs as a whole improved.
[0024]
[Evaluation 10]
Fifteen men and women with an average age of 47 years who were aware of “easy to get angry” took a tablet containing 900 mg of coral calcium three times a day for three months. One patient was strongly aware before ingestion and 14 were weakly aware. Three months later, 12 cases were not aware of “easy to get angry” at all, 2 cases were weak and 1 case was strongly aware, but overall, “easy to get angry” was improved.
[0025]
[Evaluation 11]
Eleven men and women with an average age of 45 who were aware of “anxiety” took tablets containing 900 mg of coral calcium three times a day for three months. One patient was strongly aware before ingestion and 10 were weakly aware. Three months later, 7 cases were not aware of “anxiety” at all, 3 cases were weak and 1 case was strongly aware, but it can be said that “anxiety” was improved as a whole.
[0026]
[Evaluation 12]
Sixteen men and women with an average age of 40 who were aware of “Iraira” took tablets containing 900 mg of coral calcium three times a day for three months. Prior to ingestion, 1 case was strongly aware, 10 cases were normal, and 14 cases were weak. Three months later, 7 cases were not aware of “Iraira” at all and 9 cases were weakly aware, but it can be said that “Iraira” was improved as a whole.
[0027]
[Evaluation 13]
Eleven men and women with an average age of 42 who were aware of “excitement” took coral calcium 900 mg tablets three times a day for three months. One patient was strongly aware before ingestion and 10 were weakly aware. Three months later, 6 cases were not aware of “excitement” at all, and 4 cases were weakly aware, but it can be said that “excitement” improved as a whole.
[0028]
[Evaluation 14]
Seventeen men and women with an average age of 45 years who were aware of “stiff shoulders” took tablets containing 900 mg of coral calcium three times a day for three months. Five cases were strongly aware before ingestion, 7 cases were normal, and 3 cases were weak. Three months later, 6 cases were not aware of “stiff shoulders” at all, and 6 cases were weakly aware, but it can be said that “stiff shoulders” improved as a whole.
[0029]
[Evaluation 15]
Fourteen men and women with an average age of 43, who were aware of “Darusa”, took tablets containing 900 mg of coral calcium three times a day for three months. Seven cases were aware of normal level and 11 cases were weak before taking. Three months later, 5 cases were not aware of "Darusa" at all, and 8 cases were weakly aware, but it can be said that "Darusa" improved as a whole.
[0030]
[Evaluation 16]
Eight men and women with an average age of 47 who were aware of a “dull feeling” ingested tablets containing 900 mg of coral calcium three times a day for three months. One patient had a normal awareness before ingestion and seven were weak. After 3 months, 4 cases were not aware of “blurred feeling” at all, and 3 cases were weakly aware, but it can be said that “blurred feeling” was improved as a whole.
[0031]
[Evaluation 17]
Thirteen men and women with an average age of 43 who were aware of “somnolence” took tablets containing coral calcium 900 mg three times a day for 3 months. Three cases were strongly aware before ingestion and 10 cases were normal. Three months later, 5 cases were not aware of “somnolence” at all, and 3 cases were weakly aware, but it can be said that “somnolence” improved as a whole.
[0032]
[Evaluation 18]
Six men and women with an average age of 48 years who were aware of “arrhythmia” took a tablet containing 900 mg of coral calcium three times a day for three months. 6 cases were strongly aware before ingestion. Three months later, 4 cases were not aware of “arrhythmia” at all, and 2 cases were weakly aware, but it can be said that “arrhythmia” improved as a whole.
[0033]
[Evaluation 19]
Twelve men and women with an average age of 20 years were given 1500 mg of coral calcium after being stressed by a number filling game. On the other hand, a similar control group given similar stress took 1500 mg of dechristlin. The electroencephalogram was measured with an NEC EE1000 14-channel multi-use electroencephalograph, and the electroencephalogram was derived from 14 locations on the head, and was mainly attached to the electroencephalogram in the alpha wave band (8-12 Hz). Analyzed by graphy. An α wave is an electroencephalogram that appears in a relaxed state, and it is said that when it increases, it relaxes and “easy to get angry” and “anxiety” are improved.
[0034]
The α wave of the group ingesting 1500 mg of coral calcium increased to 0.0 μV after 5 minutes and 1.0 μV after 30 minutes. On the other hand, the α wave of the control group ingesting 1500 mg of dechristlin decreased to 1.8 μV after 5 minutes and 0.5 μV after 30 minutes.
[0035]
When the α wave was observed only in the right brain, which is important for relaxation, the population taking 1500 mg of coral calcium increased to 50 μV after 5 minutes and 59 μV after 10 minutes.
[0036]
On the other hand, in the control group ingesting 1500 mg of dechristlin, it decreased to 40 μV after 5 minutes and to 30 μV after 10 minutes.
[0037]
Next, as for the α wave at the top of the head, the population ingesting 1500 mg of coral calcium increased to 2.1 μV after 5 minutes, 3.1 μV after 10 minutes, and 3.4 after 20 minutes. On the other hand, the control group ingesting 1500 mg of dechristlin decreased to 3.0 μV after 5 minutes, 2.5 μV after 10 minutes, and 2.0 μV after 20 minutes.
[0038]
[Evaluation 20]
Two men in their 20s took coral containing 200 mg of coral calcium. Using a 2-channel memory PH measuring device manufactured by Chemical Instruments Co., Ltd., PH sensors were installed in the stomach and cardia, and PH in the stomach and PH in the lower esophagus were measured. The gastric pH before ingestion was 1-2, and the lower esophageal PH was 6.
[0039]
In addition, when one candy was eaten, the pH in the stomach increased to 3 or 4, and the lower esophageal PH increased to 7. Moreover, the same thing was observed when eating 2 grains, 3 grains and 4 grains.
[0040]
As described above, it was found that the sputum containing 200 mg of coral calcium neutralizes PH in the stomach and lower esophagus, so a clinical trial was conducted.
[0041]
Nine people in their 50s with an average age of 50 showing heartburn symptoms took 1-2 sputum containing 200 mg of coral calcium. In all 9 cases, disappearance of heartburn symptoms was observed. Ten people in their 50s with an average age of stomach discomfort symptom ingested 1-2 sputum containing 200 mg of coral calcium. In 2 cases, disappearance of symptoms of stomach discomfort was observed, and in 8 cases, improvement was observed.
[0042]
[Evaluation 21]
Four men with hyperuricemia took tablets containing 900 mg of coral calcium three times a day or 500 ml of PH8-9 coral calcium water containing 40 mg of calcium and 20 mg of magnesium daily for 6 months. The average serum uric acid level before ingestion was 9.0 mg / dl, but after 3 months, the average value decreased to 6.0 mg / dl, reducing gout pain and improving limb stones or urinary tract stones. It was done.
[0043]
[Evaluation 22]
Four men with renal disease who had high serum creatinine levels took tablets containing 900 mg of coral calcium three times a day for three months. The mean serum creatinine value before ingestion was 6.7 mg / dl, but it decreased to 5.5 mg / dl after 6 months. Moreover, although the mean blood pressure before ingestion of these patients was 160.21 mmHg, the average value after 6 months decreased to 140.54 mmHg. The average serum potassium before ingestion was 5.0 mEq / l, but the average value after 3 months decreased to 4.0 mEq / l.
[0044]
[Evaluation 23]
Three men with kidney disease took tablets containing 900 mg of coral calcium three times a day for 6 months. The average phosphorus value before ingestion was 5.0 mg / dl, but after 3 months it decreased to 4.2 mg / dl and edema was also improved.
[0045]
The mean serum iron level before intake was 40 μg / dl, but increased to 60 μg / dl after 3 months.
[0046]
[Intake form of coral calcium]
Coral calcium ingestion that exhibits the above effects includes tablets, capsules, powders, granules, sprinkling agents, candy, gum, chocolate, cookies, snacks, jelly, etc. alone or in combination with other ingredients Examples include confectionery, various retort foods, curry roux, stew, noodles, milk blends, and beverages.
[0047]
【The invention's effect】
As described above, the mineral-containing composition according to the present invention is a coral fossil produced from nature, or a marine organism derived from mineralization by replacing calcium in limestone produced from marine organisms with magnesium in the ocean. It contains minerals and can be consumed easily in daily life. Also, strengthening bone density, lowering blood pressure, lowering total cholesterol, lowering triglycerides, increasing HDL, suppressing arrhythmia, suppressing palpitation, suppressing blinking, suppressing headache, improving edema of the limbs / face, suppressing anxiety and anger, suppressing irritation , Suppression of excitement, suppression of stiff shoulders, suppression of dullness, suppression of dullness, suppression of somnolence, increased brain alpha waves, improvement of heartburn and stomach discomfort due to neutralization of stomach acid, reduction of high uric acid level, kidney disease It has biological balance improvement effects such as suppression of blood pressure increase, suppression of high potassium plasma, suppression of acidosis, suppression of high phosphorus plasma, suppression of edema, and suppression of anemia.
Claims (5)
骨密度強化、血圧低下、総コレステロール低下、中性脂肪低下、HDL増加、不整脈の抑制、動悸抑制、瞬き抑制、頭痛抑制、手足・顔の浮腫改善、不安や怒りの抑制、いらいらの抑制、興奮の抑制、肩こりの抑制、だるさの抑制、ぼんやり感の抑制、傾眠の抑制、脳のα波増加、胃酸中和による胸焼けや胃部不快感の改善、高尿酸値の低下、腎臓病に付随する血圧上昇の抑制、高カリウム血漿の抑制、アシドーシスの抑制、高リン血漿の抑制、浮腫抑制、貧血抑制の作用を有することを特徴とする生体バランス改善効果を備えたミネラル含有組成物。Coral fossils produced from nature or marine organism-derived minerals that are mineralized by replacing calcium in limestone produced from marine organisms with magnesium in the ocean,
Strengthening bone density, lowering blood pressure, lowering total cholesterol, lowering triglycerides, increasing HDL, suppressing arrhythmia, suppressing palpitation, suppressing blinking, reducing headache, improving edema of the limbs / face, suppressing anxiety and anger, suppressing irritation, excitement , Suppression of stiff shoulder, suppression of dullness, suppression of somnolence, suppression of somnolence, increase of brain alpha wave, improvement of heartburn and stomach discomfort due to neutralization of stomach acid, decrease in high uric acid level, associated with kidney disease A mineral-containing composition having an effect of improving a biological balance, characterized by suppressing blood pressure increase, high potassium plasma, acidosis, high phosphorus plasma, edema, and anemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002340508A JP2004175680A (en) | 2002-11-25 | 2002-11-25 | Mineral-containing composition having improving effect on biological balance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002340508A JP2004175680A (en) | 2002-11-25 | 2002-11-25 | Mineral-containing composition having improving effect on biological balance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004175680A true JP2004175680A (en) | 2004-06-24 |
Family
ID=32703104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002340508A Pending JP2004175680A (en) | 2002-11-25 | 2002-11-25 | Mineral-containing composition having improving effect on biological balance |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004175680A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007223924A (en) * | 2006-02-22 | 2007-09-06 | Coral Biotech Co Ltd | Antihypertensive |
| JP2011073999A (en) * | 2009-09-30 | 2011-04-14 | Coral International Kk | Bone density increasing agent |
| EP2574241A1 (en) * | 2011-09-30 | 2013-04-03 | E Ethno'prospections | Micro-nutritional speciality made of calcium carbonate and plants |
| CN103109947A (en) * | 2013-03-15 | 2013-05-22 | 杭州艺福堂茶业有限公司 | Black oolong tea bag and preparation method thereof |
| JP2013116911A (en) * | 2007-08-07 | 2013-06-13 | Mg Pharma Kk | Hypotensive agent |
| CN104398867A (en) * | 2014-10-28 | 2015-03-11 | 刘林强 | Pharmaceutical composition treating arrhythmia coronary heart disease |
| US9446087B2 (en) * | 2006-10-24 | 2016-09-20 | David W. Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
| JP2017001966A (en) * | 2015-06-05 | 2017-01-05 | 株式会社東洋新薬 | Blood triglyceride elevation-inhibiting composition |
| CN107951940A (en) * | 2017-11-16 | 2018-04-24 | 湖北大学 | A kind of antihypertensive drug composition |
| JP2021080238A (en) * | 2019-11-22 | 2021-05-27 | 佰吉ジャパン生物技術開発株式会社 | Composition that prevents or reduces hyperuricemia and production method thereof |
-
2002
- 2002-11-25 JP JP2002340508A patent/JP2004175680A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007223924A (en) * | 2006-02-22 | 2007-09-06 | Coral Biotech Co Ltd | Antihypertensive |
| US11207368B2 (en) | 2006-10-24 | 2021-12-28 | Murray Mary A | Anti-resorptive and bone building dietary supplements and methods of use |
| US9446087B2 (en) * | 2006-10-24 | 2016-09-20 | David W. Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
| JP2013144696A (en) * | 2007-08-07 | 2013-07-25 | Mg Pharma Kk | Anti-hypertensive agent |
| JP2013116911A (en) * | 2007-08-07 | 2013-06-13 | Mg Pharma Kk | Hypotensive agent |
| JP2011073999A (en) * | 2009-09-30 | 2011-04-14 | Coral International Kk | Bone density increasing agent |
| FR2980670A1 (en) * | 2011-09-30 | 2013-04-05 | Ethno Prospections E | MICRONUTRITIONAL SPECIALTY BASED ON SEDIMENTARY ROCKS AND PLANTS |
| EP2574241A1 (en) * | 2011-09-30 | 2013-04-03 | E Ethno'prospections | Micro-nutritional speciality made of calcium carbonate and plants |
| CN103109947A (en) * | 2013-03-15 | 2013-05-22 | 杭州艺福堂茶业有限公司 | Black oolong tea bag and preparation method thereof |
| CN104398867A (en) * | 2014-10-28 | 2015-03-11 | 刘林强 | Pharmaceutical composition treating arrhythmia coronary heart disease |
| JP2017001966A (en) * | 2015-06-05 | 2017-01-05 | 株式会社東洋新薬 | Blood triglyceride elevation-inhibiting composition |
| CN107951940A (en) * | 2017-11-16 | 2018-04-24 | 湖北大学 | A kind of antihypertensive drug composition |
| JP2021080238A (en) * | 2019-11-22 | 2021-05-27 | 佰吉ジャパン生物技術開発株式会社 | Composition that prevents or reduces hyperuricemia and production method thereof |
| WO2021100837A1 (en) * | 2019-11-22 | 2021-05-27 | 佰吉ジャパン生物技術開発株式会社 | Composition for preventing or reducing hyperuricemia, and method for producing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Šamec et al. | Cruciferous (brassicaceae) vegetables | |
| Yadav et al. | Determination of exposure and probable ingestion of fluoride through tea, toothpaste, tobacco and pan masala | |
| JP2004175680A (en) | Mineral-containing composition having improving effect on biological balance | |
| JP2006036681A (en) | Drink having action of inhibiting increase of neutral fat in blood | |
| JP5357372B2 (en) | Skin symptom improving agent | |
| JP4672304B2 (en) | Lipolysis accelerator | |
| Khater | Herbal and Horticultural Remedies:: Gardening for the Elderly and Physically and Mentally Disabled | |
| Windmann | Shilajit: the ayurvedic adaptogen for anti-aging and immune power | |
| Nieder et al. | Medicinal uses of soil components, geophagia and podoconiosis | |
| Gittleman | Super Nutrition for Menopause: Take Control of Your Life and Enjoy New Vitality | |
| KR100584153B1 (en) | Constipation solution for improving constipation by using herbal medicine and its manufacturing method | |
| KR20050080501A (en) | A making method of health assistance food for high blood pressure, fatness, diabetes patients. | |
| JP2003230360A (en) | Ice cream having health enhancement effect and beauty/ diet effect, and method for producing the same | |
| JP5794761B2 (en) | Anti-fatigue agent containing sesamin and vitamin E | |
| US20020090419A1 (en) | Food formulations with a high calcium content | |
| ES2314636T3 (en) | COMPOSITION; USE OF A COMPOSITION AND A PROCEDURE TO PREVENT FAT ABSORPTION. | |
| JP7505831B2 (en) | Hypertension improving agent containing seaweed extract, and functional foods, quasi-drugs and medicines containing said hypertension improving agent | |
| Monte | The complete guide to natural healing | |
| KR20060054804A (en) | Constipation | |
| CN108420891A (en) | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| Floury et al. | Digestion and oral comfort of cheese developed to meet the sensory and nutritional needs of the elderly | |
| KR20200062988A (en) | Manufacturing method of balsamic dressing for salad | |
| TW201701889A (en) | Urinary system symptom amelioration agent | |
| Hobbs | Natural Therapy for Your Liver: Herbs and Other Natural Remedies for a Healthy Liver | |
| JP2025081772A (en) | Bloodstream ameliorating composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050601 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050601 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20050601 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090310 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090716 |